Table 3. Influence of treatment components and diagnosis on parameters.

		Glucose (%)1		Triglycerides (%)2		HDL-C (mmol/l)3		LDL-C (mmol/l)2		Insulin (%)4		FFA (mmol/l)5
Model	N	152*		149**		154**		153**		150*		151*
		β	P	β	P	β	P	β	P	β	P	β	P
1	Controls (N = 61)	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	Nephroblastoma (N = 67)	−2.9	0.24	30.2	0.001	−0.05	0.36	0.16	0.22	22.4	0.132	0.02	0.53
	Neuroblastoma (N = 36)	−1.7	0.55	12.9	0.24	−0.10	0.105	0.44	0.004	−8.1	0.60	0.05	0.29
2	Controls (N = 61)	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	Chemotherapy (N = 90)	1.8	0.55	28.3	0.009	−0.12	0.054	0.45	0.003	27.6	0.139	0.05	0.28
	Nephrectomy (N = 74)	5.3	0.47	−2.3	0.83	0.07	0.27	−0.40	0.014	18.8	0.33	−0.13	0.005
	Adrenalectomy (N = 49)	−8.7	0.001	−10.6	0.24	−0.06	0.31	0.00	1.00	−20.1	0.152	0.04	0.32
	Rx abdomen (N = 42)	2.3	0.108	33.8	0.005	0.02	0.71	0.32	0.049	−10.6	0.53	0.16	<0.001
3	Controls (N = 61)	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	Pancreas – part (N = 15)	3.9	0.28	19.7	0.159	0.09	0.23	0.46	0.018	−3.7	0.85	0.09	0.121
	Pancreas – total (N = 27)	10.5	0.002	44.8	0.002	−0.07	0.30	0.22	0.23	20.1	0.30	0.23	<0.001
4	Controls (N = 61)	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref	ref
	Liver – part (N = 19)	9.5	0.013	39.1	0.015	−0.09	0.28	0.30	0.151	16.9	0.46	0.17	0.002
	Liver – total (N = 23)	6.3	0.056	28.4	0.030	0.05	0.45	0.35	0.044	5.0	0.78	0.16	0.001

^*subjects with treatment for diabetes excluded.

^**subjects with treatment for dyslipidemia excluded.

¹Corrected for age, sex, BMI, physical activity.

²Corrected for age, sex, BMI, smoking, physical activity.

³Corrected for age, sex, BMI, smoking.

⁴corrected for age, sex, SES, BMI.

⁵corrected for age, sex, physical activity. Glucose, insulin, HOMA and triglycerides levels were normally distributed after log-transformation and were expressed in percentages. ref = reference value (control subjects).

Multiple linear regression analyses were performed using the following strategy: Model 1: the effects of both diagnoses (dummy variables) were added. Model 2: the effects of chemotherapy, nephrectomy, adrenalectomy, abdominal radiotherapy (dummy variables) were added. Additional linear regression analyses were performed according to the following strategy: Model 3: the effects of radiotherapy to the total pancreas and on part of the pancreas (Figure 1) (dummy variables) were added. Model 4: the effect of radiotherapy on the total liver and on part of the liver (Figure 1) (dummy variables) were added. Model 3 and 4 were additionally corrected for the treatment components that were significant in Model 2. P-values indicate the significance of the difference with control subject.